Chimeric AAV Capsid Loop Substitution for Tissue Tropism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors have limitations in terms of tropism, making it challenging to target specific cell types or tissues effectively for gene therapy applications.
Innovation Solution
Development of novel chimeric AAV capsids with altered tropism profiles by substituting amino acids in specific regions, such as between β-sheet G and β-sheet H or β-sheet G and β-sheet I, from one AAV serotype with those from another, while maintaining production and purification compatibility with standard protocols.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If amino acid substitution is performed to alter tropism profile, then tissue targeting capability is improved, but capsid structure complexity increases
Solution Approach 1:
The patent applies local quality by performing site-specific amino acid substitutions in targeted regions (β-sheet G-H and β-sheet G-I loops) of the AAV capsid protein rather than global modifications. This localized approach alters tropism through specific residue changes (e.g., positions 547-559 in AAV9) while preserving the overall capsid structure and production compatibility.
Solution Approach 2:
The invention segments the capsid modification approach by dividing the capsid protein into distinct functional regions (β-sheets G through I) and selectively modifying only the loop regions between these sheets. This segmentation allows independent optimization of tropism without affecting other critical capsid functions.
2Manufacturing precision
If chimeric capsid design is implemented to achieve novel tropism, then gene delivery specificity is improved, but production compatibility may deteriorate
Solution Approach 1:
The patent applies parameter changes by systematically varying amino acid residues at specific positions (547-559 and other loop regions) to optimize tropism while maintaining production characteristics. The modifications are designed to change local structural parameters without fundamentally altering the capsid assembly process or purification requirements.
Solution Approach 2:
The invention creates composite capsid structures by combining amino acid sequences from different AAV serotypes (e.g., AAV9 backbone with AAV6 loop regions) to generate chimeric capsids that exhibit hybrid properties - the desired novel tropism from the donor serotype loops while maintaining the production and purification characteristics of the parental serotype backbone.
3Adaptability or versatility
If loop region substitution is performed between β-sheets, then tropism profile is improved, but capsid production titer may deteriorate
Solution Approach 1:
The patent performs localized amino acid substitutions specifically in the loop regions between β-sheets G-H and G-I, preserving the intact β-sheet core structure that is critical for capsid assembly and stability. This localized modification approach minimizes disruption to the overall capsid formation process and maintains production titers.
Solution Approach 2:
The invention applies partial action by introducing minimal modifications - only the essential amino acid residues required for tropism alteration are changed, rather than extensive modifications. This conservative approach (e.g., changing 3-5 key residues in the loop region) achieves the desired tropism shift while minimizing negative impacts on capsid production efficiency.
Data Source
AI summary
The present invention provides novel chimeric AAV capsid proteins and their use in adeno-associated viral (AAV) vectors, including recombinant AAV (rAAV) vectors, and compositions thereof. The chimeric AAV capsid proteins have advantageous properties including tropism that differs from that of the parental AAV capsid.